ARTICLE | Company News
TapImmune, Mayo Clinic deal
March 31, 2014 7:00 AM UTC
TapImmune signed an exclusive option agreement with Mayo for peptide epitopes targeting folate receptor 1 ( FOLR1; FR-alpha) in breast and ovarian cancer. TapImmune said that a Phase I trial evaluating a multi-epitope FOLR1 peptide vaccine conducted by Mayo is ongoing. TapImmune declined to disclose details, and Mayo could not be reached. ...